Gd-CA

Catharina Ziekenhuis Eindhoven · Phase 1 active Small molecule

At a glance

Generic name	Gd-CA
Sponsor	Catharina Ziekenhuis Eindhoven
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients. (PHASE2)
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) (PHASE1, PHASE2)
Thoracic Fluid Assessment by Contrast-enhanced Magnetic Resonance Imaging and Bioimpedance (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gd-CA CI brief — competitive landscape report
Gd-CA updates RSS · CI watch RSS
Catharina Ziekenhuis Eindhoven portfolio CI